Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 9/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23807876 | 1.00 | EPHX2 (0.42) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL15812124 | 1.00 | EPHX2 (0.42) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL31759412 | 0.85 | EPHX2 (0.40) | EPHX2NR1H2USP2SMN1; SMN2HPGD | |
| SCHEMBL21908790 | 0.84 | NR1H2 (0.38) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL31279448 | 0.83 | EPHX2 (0.43) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL27171881 | 0.83 | NR1H2 (0.41) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL24695414 | 0.83 | NR1H2 (0.41) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL24087434 | 0.83 | NR1H2 (0.41) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL26961826 | 0.83 | EPHX2 (0.43) | EPHX2NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL28914071 | 0.82 | NR1H2 (0.44) | EPHX2NR1H2USP2SMN1; SMN2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4604955-A1 | USE OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 COMPOUNDS | Pfizer Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605076-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS | Pfizer Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250188059-A1 | NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 | ARUM THERAPEUTICS INC (KR) | 2025-06-12 | — | — | US | disclosed |
| CN-120129681-A | Modulators of protein 3 (PNPLA 3) containing Patatin-like phospholipase domains | 辉瑞大药厂 | 2025-06-10 | — | — | CN | disclosed |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4552639-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR (GIST) | Universität Duisburg-Essen (DE) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025072673-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS IRE 1 INHIBITORS | AL22.02.01, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119546604-A | Pyrido [3,2-D ] pyrimidines as HPK1 inhibitors | 默克专利有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4507789-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4495111-A1 | NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 | Arum Therapeutics Inc (KR) | 2025-01-22 | — | — | EP | disclosed |
| CN-118891255-A | Novel compounds and their use for inhibiting checkpoint kinase 2 | 阿鲁姆治疗公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4450501-A1 | CDK9 INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024084360-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024084363-A1 | USE OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 COMPOUNDS | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023201185-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023177233-A1 | NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 | (주)아름테라퓨틱스 | 2023-09-21 | — | — | WO | disclosed |
| CN-116354957-A | CDK9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188059-A1 | NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 | CHEK2, CHEK1, PARP2 | EPHX2 2995/4885NR1H2 3825/4885USP2 769/4885 |
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, PPIP5K2, IP6K1 | EPHX2 1372/4885NR1H2 3216/4885USP2 2721/4885 |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | CDK9, CDK19, CDKL1 | EPHX2 3268/4885NR1H2 1620/4885USP2 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.